-
Using blood pressure, BUN, serum sodium, and presence of peripheral arterial disease as predictors of mortality in heart failure patients, 67% who had 3 or more factors died within 6 months and would qualify for the Medicare hospice benefit.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
The statistics are not new news: "Only about 7% of sites enroll what they say they will enroll," said William Flohrs, PharmD, Associate Clinical Research Consultant, Eli Lilly and Company, Indianapolis, IN.1 "From 1997 to 2003, the studies completed on time decreased from 18% to 6%."
-
Ethicists and others continue to find it troubling that payments to research participants are part of the recruitment process.
-
Determining the ability of patients with Alzheimer's disease to give consent for participation in research can present challenges to researchers and IRBs.
-
It could be argued that successful clinical trials depend on a variety of factors. But perhaps the glue that holds it all together is the study coordinator.
-
From a bioethical perspective, payments to research participants are complicated, an expert says.
-
-
Although Enzyme-Immunoassay (EIA) tests have replaced cytotoxin assays for diagnosis of Clostridium difficile-associated diarrhea (CDAD) in most US laboratories, the changing epidemiology of this disease suggests that an adjustment in diagnostic testing algorithms is needed.
-
A retrospective review of 211 inpatients admitted to the US Navy hospital ship USNS Comfort in early 2003 revealed 57 patients with A. baumannii infection.
